Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MAAQ NASDAQ:OBSV NASDAQ:PYRGF NASDAQ:RVPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMAAQMana Capital Acquisition$3.79-0.9%$3.93$5.35▼$10.25$30.79MN/A33,075 shs15,439 shsOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shs200 shsPYRGFPyroGenesis Canada$0.19+11.2%$0.26$0.17▼$0.71$32.56M0.8114,627 shs2,403 shsRVPHReviva Pharmaceuticals$0.44-0.2%$0.45$0.30▼$4.28$30.08M-0.041.99 million shs785,993 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMAAQMana Capital Acquisition0.00%+1.90%+0.48%-7.44%+1,162.77%OBSVObsEva0.00%0.00%0.00%-75.00%-75.00%PYRGFPyroGenesis Canada+11.18%+1.53%-29.54%-43.96%-66.43%RVPHReviva Pharmaceuticals-0.18%+0.75%-3.85%-39.10%-65.98%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMAAQMana Capital Acquisition$3.79-0.9%$3.93$5.35▼$10.25$30.79MN/A33,075 shs15,439 shsOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shs200 shsPYRGFPyroGenesis Canada$0.19+11.2%$0.26$0.17▼$0.71$32.56M0.8114,627 shs2,403 shsRVPHReviva Pharmaceuticals$0.44-0.2%$0.45$0.30▼$4.28$30.08M-0.041.99 million shs785,993 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMAAQMana Capital Acquisition0.00%+1.90%+0.48%-7.44%+1,162.77%OBSVObsEva0.00%0.00%0.00%-75.00%-75.00%PYRGFPyroGenesis Canada+11.18%+1.53%-29.54%-43.96%-66.43%RVPHReviva Pharmaceuticals-0.18%+0.75%-3.85%-39.10%-65.98%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMAAQMana Capital Acquisition 0.00N/AN/AN/AOBSVObsEva 0.00N/AN/AN/APYRGFPyroGenesis Canada 0.00N/AN/AN/ARVPHReviva Pharmaceuticals 3.14Buy$5.201,075.67% UpsideCurrent Analyst Ratings BreakdownLatest OBSV, PYRGF, MAAQ, and RVPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025RVPHReviva PharmaceuticalsRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.00 ➝ $3.008/18/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.008/15/2025RVPHReviva PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/15/2025RVPHReviva PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.00 ➝ $2.006/27/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMAAQMana Capital AcquisitionN/AN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/A$0.41 per shareN/APYRGFPyroGenesis Canada$9.14M3.96N/AN/A($0.01) per share-19.30RVPHReviva PharmaceuticalsN/AN/AN/AN/A$0.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMAAQMana Capital AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AOBSVObsEva-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/APYRGFPyroGenesis Canada-$21.12M-$0.03N/A∞N/A-115.14%N/A-60.81%N/ARVPHReviva Pharmaceuticals-$29.92M-$0.65N/AN/AN/AN/AN/A-259.17%11/13/2025 (Estimated)Latest OBSV, PYRGF, MAAQ, and RVPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025RVPHReviva Pharmaceuticals-$0.15-$0.12+$0.03-$0.12N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMAAQMana Capital AcquisitionN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/APYRGFPyroGenesis CanadaN/AN/AN/AN/AN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMAAQMana Capital AcquisitionN/AN/AN/AOBSVObsEvaN/A0.610.61PYRGFPyroGenesis CanadaN/A0.600.50RVPHReviva PharmaceuticalsN/A0.900.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMAAQMana Capital Acquisition68.44%OBSVObsEva17.52%PYRGFPyroGenesis Canada0.03%RVPHReviva Pharmaceuticals63.18%Insider OwnershipCompanyInsider OwnershipMAAQMana Capital AcquisitionN/AOBSVObsEva14.40%PYRGFPyroGenesis Canada47.68%RVPHReviva Pharmaceuticals27.18%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMAAQMana Capital Acquisition18.13 millionN/ANot OptionableOBSVObsEva5077.97 million66.74 millionNot OptionablePYRGFPyroGenesis Canada90187.53 million96.34 millionNo DataRVPHReviva Pharmaceuticals568.00 million49.52 millionOptionableOBSV, PYRGF, MAAQ, and RVPH HeadlinesRecent News About These CompaniesReviva Pharmaceuticals (NASDAQ:RVPH) vs. Ironwood Pharmaceuticals (NASDAQ:IRWD) Critical ReviewSeptember 8, 2025 | americanbankingnews.comRVPH: There May Be A Faster WayAugust 19, 2025 | finance.yahoo.comReviva Pharmaceuticals Advances Schizophrenia TreatmentAugust 18, 2025 | tipranks.comReviva Pharmaceuticals price target lowered to $3 from $7 at Roth CapitalAugust 18, 2025 | msn.comReviva Narrows Loss 23% in Fiscal Q2August 14, 2025 | aol.comAReviva Reports Second Quarter 2025 Financial Results and Recent Business HighlightsAugust 14, 2025 | globenewswire.comReviva Pharmaceuticals Holdings, Inc. (RVPHW) - Yahoo FinanceJuly 5, 2025 | finance.yahoo.comReviva Pharmaceuticals Holdings, Inc. (RVPH) - Investing.comJune 29, 2025 | investing.comReviva Dives on Stock OfferingJune 26, 2025 | baystreet.caReviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public OfferingJune 26, 2025 | globenewswire.comReviva Pharmaceuticals stock falls after announcing public offeringJune 25, 2025 | za.investing.comReviva Pharmaceuticals Holdings, Inc. Announces Proposed Public OfferingJune 25, 2025 | globenewswire.comRVPH: Open Label Extension Results & Key Opinion Leader DiscussionJune 5, 2025 | finance.yahoo.comReviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid ConferenceJune 5, 2025 | globenewswire.comReviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in SchizophreniaJune 2, 2025 | globenewswire.comReviva to Participate in Upcoming Investor Conferences in May 2025May 20, 2025 | santelog.comSReviva Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 15, 2025 | globenewswire.comReviva to Participate in the A.G.P. Healthcare Company ShowcaseMay 13, 2025 | finance.yahoo.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Icon (ICLR), Reviva Pharmaceuticals Holdings (RVPH) and SurModics (SRDX)May 4, 2025 | theglobeandmail.comReviva to Participate in the Citizens Life Sciences ConferenceApril 29, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOBSV, PYRGF, MAAQ, and RVPH Company DescriptionsMana Capital Acquisition NASDAQ:MAAQ$3.79 -0.03 (-0.88%) As of 09/12/2025Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.ObsEva NASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.PyroGenesis Canada NASDAQ:PYRGF$0.19 +0.02 (+11.18%) As of 09/12/2025 03:06 PM EasternPyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.Reviva Pharmaceuticals NASDAQ:RVPH$0.44 0.00 (-0.18%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.44 0.00 (-0.07%) As of 09/12/2025 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
